Key result
Imatinib therapy in newly diagnosed CML patients was associated with cardiotoxicity (reduced ejection fraction and wall abnormalities) in 11.43% of patients at 12 months (P=0.006).
Why the study?
Cardiovascular health has emerged as an important consideration in CML patients, with some studies reporting an increased incidence of CHF during Imatinib therapy.
Does Imatinib therapy induce cardiotoxicity in newly diagnosed CML patients?
Cohort (n=70)
Does Imatinib therapy induce cardiotoxicity in newly diagnosed CML patients?
Imatinib therapy in newly diagnosed CML patients is associated with asymptomatic cardiac dysfunction in over 10% of patients at 1 year, highlighting the need for routine cardiac monitoring.
Answers are grounded in this paper and cite their sources.
May warrant echocardiographic monitoring in CML patients on imatinib; leaves open causal confirmation and outcome impact in prospective trials.
INTRODUCTION: The success of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML) has increased the focus on survivorship and late toxicity in oncological care. Cardiovascular (CV) health has emerged as an important consideration in patients of CML. Some studies have shown an increased incidence of CHF with Imatinib therapy. This study was conducted to assess the cardiac functions in patients of CML on Imatinib therapy. METHODS: Seventy newly diagnosed CML patients started on Imatinib therapy having normal baseline cardiac functions as assessed by two-dimensional echocardiography and multigated acquisition (MUGA) scan were included in the study. Further assessment of cardiac functions at 3, 6, and 12 months was done by MUGA scan. RESULTS: At 3, 6, and 12 months of follow-up, 7.14%, 10%, and 11.43% of patients, respectively, showed evidence of cardiotoxicity in the form of reduced ejection fraction and wall abnormalities on MUGA scan ( P = 0.58, 0.013, and 0.006, respectively). CONCLUSION: Cardiac dysfunction was seen in 11.43% of patients on Imatinib therapy for CML, though none of them were symptomatic. CML patients on Imatinib therapy must be monitored for cardiac functions, especially if they have other CV risk factors.
No takes yet. Share an insight, caveat, or question.
Chakravarthy et al. (2022) conducted a cohort in Chronic myeloid leukemia (CML) (n=70). Imatinib therapy was evaluated on Cardiotoxicity in the form of reduced ejection fraction and wall abnormalities on MUGA scan (p=0.006). Imatinib therapy in newly diagnosed CML patients was associated with cardiotoxicity (reduced ejection fraction and wall abnormalities) in 11.43% of patients at 12 months (P=0.006).
Synapse has enriched 10 related papers. Consider them for comparative context: